Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + BEAM before ASCT and Pembrolizumab maintenance in R/R Classic Hodgkin Lymphoma
NCT06377540Phase 2Recruiting
- Sponsor
- Masonic Cancer Center
- Start
- Dec 2024
- Primary completion
- Sep 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in classic Hodgkin lymphoma (cHL), sponsored by Masonic Cancer Center. Primary endpoint: Progression-Free Survival at 1 year. Started Dec 2024; status: recruiting.
02
Drugs
03
Conditions
classic Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT06377540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06377540.